With respect to cancer risk, MSH2 and MLH1 have similar risk profiles but are subtly distinct from one another whereas MSH6 has a unique risk profile associated with colorectal cancer and endometrial cancer and PMS2 appears, on prospective evidence, to be primarily associated with endometrial cancer and little else [12, 13]. Here, MLH1 is linked to endometrial cancer.